• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Sri Lanka Pharmaceuticals and Healthcare Report Q1 2013 - Product Image

Sri Lanka Pharmaceuticals and Healthcare Report Q1 2013

  • Published: February 2013
  • Region: Sri Lanka
  • 71 pages
  • Business Monitor International

BMI View

Sri Lanka's negative pharmaceutical trade balance is expected to widen over the next five years.

In an attempt to reduce medical costs, the government announced in its 2011 budget that pharmaceutical products would be exempt from the port and airport levy, with the changes relating to drugs, medical devices and equipment. Although domestic manufacturing will struggle to compete with cheap medicines from India, we expect local producers to increase capacity considerably over the medium term.

Headline Expenditure Projections

- Pharmaceuticals: LKR50.68bn (US$459mn) in 2011 to LKR59.90bn (US$501mn) in 2012; +18.1% in local currency terms and +9.3% in US dollar terms.

- Healthcare: LRK176.30bn (US$1.60bn) in 2011 to LKR188.46bn (US$1.58bn) in 2012; +6.9% in local currency terms and -1.1% in US dollar terms.

- Medical devices: LRK11.20bn (US$101mn) in 2011 to LKR11.96bn (US$100mn) in 2012; +6.8% in local currency terms and -1.2% in US dollar terms.

BMI Industry View 7

SWOT 9

Political 11

Economic 12

Business Environment 13

Industry Forecast 14

Pharmaceutical Market Forecast 14
Table: Pharmaceutical Sales Indicators 14

Healthcare Market Forecast 16
Table: Healthcare Expenditure Indicators 17
Table: Healthcare Governmental Indicators 17
Table: Healthcare Private Indicators 18

Economic Analysis 19

Expenditure Breakdown 24
Table: Macro Indicators 25

Prescription Drug Market Forecast 26

Pharmaceutical Trade Forecast 26
Table: Exports and Imports Indicators, 2008-2016 27

Other Healthcare Data 27

Key Risks To BMI's Forecast Scenario 27

Industry Risk Reward Ratings 29

Pharmaceutical Risk Reward Ratings 29
Table: Asia Pacific Risk/Reward Ratings, Q113 29

Rewards 30

Risks 30

Market Overview 32

Market Summary 32

Industry Trends And Developments 34

Epidemiology 34

Healthcare System 37

Hospital Sector 38

Healthcare Financing 39

Clinical Trials 40

Medical Devices 40

Regulatory Development 42

Regulatory Regime 42

Regulatory Developments 44

Counterfeits 45

Pricing And Reimbursement Regimes 47

Pricing And Reimbursement Developments 48

Supply Chain 48

Competitive Landscape 51

Pharmaceutical Industry 51

Pharmaceutical Industry Developments 52

Pharmaceutical Distribution and Retail 52

Company Profile 54

State Pharmaceuticals Corporation (SPC) 54

Hemas Holdings 57

GlaxoSmithKline 60

Demographic Forecast 63

Demographic Outlook 63
Table: Sri Lanka's Population By Age Group, 1990-2020 ('000) 64
Table: Sri Lanka's Population By Age Group, 1990-2020 (% of total) 65
Table: Sri Lanka's Key Population Ratios, 1990-2020 66
Table: Sri Lanka's Rural And Urban Population, 1990-2020 66

Glossary 67

Methodology 69

Methodology 69

Risk/Reward Ratings Methodology 69

Ratings Overview 70
Table: Pharmaceutical Business Environment Indicators 70

Weighting 71
Table: Weighting Of Components 71

Sources 71

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos